Treatment with rivastigmine or galantamine and risk of urinary incontinence: Results from a Dutch database study

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 3, 2015, Pages 276-285

  Kroger, Edeltraut ^a,b   Van Marum, Rob ^c   Souverein, Patrick ^b   Carmichael, Pierre Hugues ^a   Egberts, Toine ^b,c  

^a University Laval   (Canada)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Database cohort study; Pharmacoepidemiology; Urinary incontinence

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; DATA BASE; DISEASE EXACERBATION; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; URINE INCONTINENCE; CHEMICALLY INDUCED; COHORT ANALYSIS; CROSSOVER PROCEDURE; FACTUAL DATABASE; FOLLOW UP; LONGITUDINAL STUDY; RISK FACTOR; TRENDS; URINARY INCONTINENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; CROSS-OVER STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; HUMANS; LONGITUDINAL STUDIES; MALE; NETHERLANDS; RISK FACTORS; RIVASTIGMINE; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 84925332336     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3741     Document Type: Article

References (40)

1. World Health Organization. Dementia-A Public Health Priority. Geneva, 2012.
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
3. Ouslander JG, Zarit SH, Orr NK, Muira SA. Incontinence among elderly community-dwelling dementia patients. Characteristics, management, and impact on caregivers. J Am Geriatr Soc 1990; 38: 440-5.
4. Skelly J, Flint AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc 1995; 43: 286-94.
5. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol 2008; 15: 778-88.
6. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21: 453-78.
7. Fillit HM, Doody RS, Binaso K, et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006; 4(Suppl A): S9-S24; quiz S5-S8.
8. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004; 84: 935-86.
9. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group Arch Intern Med 1998; 158: 1021-31.
10. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
11. Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 2000; 356: 568.
12. Starr JM. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease. J Am Geriatr Soc 2007; 55: 800-1.
13. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. Am J Psychiatry 1999; 156: 1470.
14. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165: 808-13.
15. Sink KM, Thomas J, 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56: 847-53.
16. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-40.
17. Stricker BH, Herings RM, Bakker A, Valkenburg HA, Sturmans F. Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance. Ned Tijdschr Geneeskd 1990; 134: 1886-9.
18. van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol 1993; 35: 400-8.
19. Stergachis A, Saunders KW, Davis RL, et al. Examples of Automated Databases. In Textbook of Pharmacoepidemiology, Kimmel S, Strom B (eds.). John Wiley & Sons, Ltd: West Sussex, England, 2006.
20. World Health Organization. WHO Collaborating Center for Drug Statistics Methodology, 2009.
21. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-25.
22. Georges J. The availbility of antidementia drugs in Europe. Eur Neurol Dis 2007; 1: 40-4.
23. Nelson L, Tanner C, Van Den Eeden S, McGuire V (eds). Neuroepidemiology: From Principles to Practice. Oxford University Press: Oxford, 2004.
24. Kröger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging 2010; 27: 663-75.
25. Nederlandse Vereniging voor Klinische Geriatrie. Richtlijn Diagnostiek en medicamenteuze behandeling van dementie. Van Zuiden Communicaties B.V.: Alphen a/d Rijn, 2005; 86-7.
26. Qaseem A, Snow V, Cross JT, Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148: 370-8.
27. Abrahamowicz M, Bartlett G, Tamblyn R, du Berger R. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol 2006; 59: 393-403.
28. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
29. Movig KL, Leufkens HG, Belitser SV, Lenderink AW, Egberts AC. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002; 11: 271-9.
30. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221.
31. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53.
32. Petri H, Leufkens H, Naus J, Silkens R, van Hessen P, Urquhart J. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990; 43: 433-9.
33. Kröger E, Berkers M, Carmichael PH, Souverein P, van Marum R, Egberts T. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands. Am J Geriatr Pharmacother 2012; 10: 373-80.
34. Allison P. Survival Analysis Using SAS: A Practical Guide. SAS Press: Cary, North Carolina, 1995.
35. Burghaus L, Eggers C, Timmermann L, Fink GR, Diederich NJ. Hallucinations in neurodegenerative diseases. CNS Neurosci Ther 2011; 16: 1755-5949.
36. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7.
37. Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc 2006; 54: 1325-33.
38. Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. Can Fam Physician - Medecin de famille canadien 2014; 60: 433-8.
39. Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004; 75: 484-8.
40. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Reglat A, Dartigues JF. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17: 655-60.